CN103420911A - 一种左旋美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐及制备方法 - Google Patents
一种左旋美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐及制备方法 Download PDFInfo
- Publication number
- CN103420911A CN103420911A CN2012104739140A CN201210473914A CN103420911A CN 103420911 A CN103420911 A CN 103420911A CN 2012104739140 A CN2012104739140 A CN 2012104739140A CN 201210473914 A CN201210473914 A CN 201210473914A CN 103420911 A CN103420911 A CN 103420911A
- Authority
- CN
- China
- Prior art keywords
- meptazinol
- tartrate
- handed
- handed meptazinol
- phenyl urethan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000365 meptazinol Drugs 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 16
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 14
- 229940095064 tartrate Drugs 0.000 claims abstract description 8
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 claims abstract description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims abstract description 5
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- LBKPGNUOUPTQKA-UHFFFAOYSA-N ethyl n-phenylcarbamate Chemical compound CCOC(=O)NC1=CC=CC=C1 LBKPGNUOUPTQKA-UHFFFAOYSA-N 0.000 claims description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 230000021962 pH elevation Effects 0.000 claims description 3
- 230000006340 racemization Effects 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- RWSHPUDCCRMHMA-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C(C(C(=O)O)(O)C(C1=CC=CC=C1)=O)(O)C(=O)O.CO Chemical compound C(C1=CC=CC=C1)(=O)C(C(C(=O)O)(O)C(C1=CC=CC=C1)=O)(O)C(=O)O.CO RWSHPUDCCRMHMA-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 230000035484 reaction time Effects 0.000 abstract description 2
- 238000001953 recrystallisation Methods 0.000 abstract description 2
- 229910000104 sodium hydride Inorganic materials 0.000 abstract description 2
- 239000012312 sodium hydride Substances 0.000 abstract description 2
- 239000004305 biphenyl Substances 0.000 abstract 1
- 125000005594 diketone group Chemical group 0.000 abstract 1
- 238000012840 feeding operation Methods 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 7
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 7
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 7
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 7
- 229960002646 scopolamine Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 ester hydrochloride Chemical class 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 4
- 229960001685 tacrine Drugs 0.000 description 4
- 238000007603 infrared drying Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- HQCHVBVOPWBDOZ-UHFFFAOYSA-N C(=O)(O)C(O)C(O)C(=O)O.C1(=CC=CC=C1)NC(=O)OCC Chemical compound C(=O)(O)C(O)C(O)C(=O)O.C1(=CC=CC=C1)NC(=O)OCC HQCHVBVOPWBDOZ-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210473914.0A CN103420911B (zh) | 2012-05-25 | 2012-11-09 | 一种左旋美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐及制备方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012101645620 | 2012-05-25 | ||
CN201210164562.0 | 2012-05-25 | ||
CN201210164562 | 2012-05-25 | ||
CN201210473914.0A CN103420911B (zh) | 2012-05-25 | 2012-11-09 | 一种左旋美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103420911A true CN103420911A (zh) | 2013-12-04 |
CN103420911B CN103420911B (zh) | 2016-06-08 |
Family
ID=47851422
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210473858.0A Expired - Fee Related CN102977024B (zh) | 2012-05-25 | 2012-11-09 | 一种(-)-美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐i型晶体 |
CN201210473914.0A Expired - Fee Related CN103420911B (zh) | 2012-05-25 | 2012-11-09 | 一种左旋美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐及制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210473858.0A Expired - Fee Related CN102977024B (zh) | 2012-05-25 | 2012-11-09 | 一种(-)-美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐i型晶体 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN102977024B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755635A (zh) * | 2014-01-20 | 2014-04-30 | 中国计量学院 | 氯卡色林衍生物及其盐的合成方法 |
CN106866733A (zh) * | 2015-12-11 | 2017-06-20 | 凯瑞康宁生物工程(武汉)有限公司 | 左旋美普他酚前药及其制备方法和用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850804A (zh) * | 2006-03-31 | 2006-10-25 | 复旦大学 | 光学纯美普他酚或其盐类及其制备方法 |
CN101020661A (zh) * | 2007-03-19 | 2007-08-22 | 复旦大学 | (-)-美普他酚氨基甲酸酯类衍生物和/或其盐类及其制备方法和用途 |
CN101786986A (zh) * | 2010-03-03 | 2010-07-28 | 复旦大学 | (+)-美普他酚前药或其盐及其制备方法 |
-
2012
- 2012-11-09 CN CN201210473858.0A patent/CN102977024B/zh not_active Expired - Fee Related
- 2012-11-09 CN CN201210473914.0A patent/CN103420911B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1850804A (zh) * | 2006-03-31 | 2006-10-25 | 复旦大学 | 光学纯美普他酚或其盐类及其制备方法 |
CN101020661A (zh) * | 2007-03-19 | 2007-08-22 | 复旦大学 | (-)-美普他酚氨基甲酸酯类衍生物和/或其盐类及其制备方法和用途 |
CN101786986A (zh) * | 2010-03-03 | 2010-07-28 | 复旦大学 | (+)-美普他酚前药或其盐及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103755635A (zh) * | 2014-01-20 | 2014-04-30 | 中国计量学院 | 氯卡色林衍生物及其盐的合成方法 |
CN106866733A (zh) * | 2015-12-11 | 2017-06-20 | 凯瑞康宁生物工程(武汉)有限公司 | 左旋美普他酚前药及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102977024B (zh) | 2016-08-24 |
CN103420911B (zh) | 2016-06-08 |
CN102977024A (zh) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103946231B (zh) | 齐墩果酸酰胺化衍生物、及其制备方法和应用 | |
CN108349933A (zh) | 制备6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二醇和6-(芳基或杂芳基)-1,3,5-三嗪-2,4-二胺的方法 | |
CN101845362A (zh) | 一种从茶油中富集油酸的方法 | |
CN106946849A (zh) | 一种右兰索拉唑及其制备方法与用途 | |
CN110563617A (zh) | 一类对香豆酸芳香衍生物及其制备方法和应用 | |
CN102993075A (zh) | 硫脲类杀虫杀螨剂丁醚脲的合成工艺 | |
CN107383012B (zh) | 含二环的咪唑醇衍生物 | |
CN108047076B (zh) | 一种奥司他韦对映异构体的制备方法 | |
EP0374095A2 (de) | Piperidinderivate | |
CN103420911A (zh) | 一种左旋美普他酚苯氨基甲酸酯-l-(+)-酒石酸盐及制备方法 | |
CN103992236B (zh) | 一种新型靶向性抗肿瘤药物及其制备方法与应用 | |
CN109627202B (zh) | 一种褪黑素衍生物及其制备方法和应用 | |
JP6506841B2 (ja) | α−アサリルアルデヒドエステル、その調製方法及びその用途 | |
CN104557969A (zh) | 一种硫酸氢氯吡格雷的生产工艺 | |
CN104876920A (zh) | 异噁唑类化合物、中间体及其制备方法和应用 | |
CN108101910A (zh) | 一种N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用 | |
CN104478974B (zh) | 一种20,23-二哌啶基-5-o-碳霉胺糖基-泰乐内酯的合成方法 | |
CN115850096A (zh) | 一种高纯度外消旋去甲肾上腺素的制备方法 | |
CN101974016A (zh) | 酰胺类化合物及其制备方法和用途 | |
CN107556276A (zh) | C‑三芳基葡萄糖苷类化合物及其制备方法和应用 | |
DE949742C (de) | Verfahren zur Herstellung von N-Allylnormorphin aus Normorphin und Allylhalogenid | |
CN103012233A (zh) | 一种n-(氨基硫代甲基)-5-氧代-1-丙基-2-吡咯烷乙酰胺的制备方法 | |
CN113527275A (zh) | 一种sklb1039化合物及其制备方法和应用 | |
CN107556316A (zh) | 含桥环的咪唑衍生物 | |
CN110105323A (zh) | 二芳基丙烷二聚体类衍生物及其药物组合物和其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160822 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Patentee after: Disha Pharmaceutical Industry Group Corp., Ltd. Patentee after: Weihai Disu Pharmaceutical Co., Ltd. Address before: 264205 No. 1 South Qingdao Road, Weihai economic and technological development, Shandong Patentee before: Disha Pharmaceutical Industry Group Corp., Ltd. Patentee before: Disha Pharmaceutical Group Shandong Disha Pharmaceutical Co., Ltd. Patentee before: Weihai Disu Pharmaceutical Co., Ltd. Patentee before: Weihai Weitai Medical Technology Development Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160608 Termination date: 20181109 |